Compare Fabrinet (FN) vs TG Therapeutics Inc (TGTX) Price & Performance

Fabrinet (FN) trades at $486.28, down 2.35% today but maintains strong analyst support with 75% buy ratings and a $769.50 consensus price target. The stock shows bullish technical signals with support at $477 and resistance at $498, while recent earnings beats highlight robust AI data-center demand driving 45% revenue growth in Q4 2026. Valuation metrics include a P/E of 37.34 and ROE of 21.33%, reflecting premium pricing for high growth.

Outlook remains positive with multi-year AI infrastructure expansion, though risks include customer concentration and margin pressure from capital expenditures. The stock offers significant upside to analyst targets if execution continues, but volatility may persist near current levels.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.